277 related articles for article (PubMed ID: 16995354)
41. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
[TBL] [Abstract][Full Text] [Related]
42. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
Lepore G; Dodesini AR; Nosari I; Trevisan R
Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
[No Abstract] [Full Text] [Related]
43. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
44. Insulin therapy for type 2 diabetes: making it work.
Dushay J; Abrahamson MJ
J Fam Pract; 2010 Apr; 59(4):E1-8. PubMed ID: 20398575
[No Abstract] [Full Text] [Related]
45. Summaries for patients. Comparison of two types of insulin added to diabetes pills in poorly controlled type 2 diabetes.
Ann Intern Med; 2008 Oct; 149(8):I-46. PubMed ID: 18936498
[No Abstract] [Full Text] [Related]
46. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
Hamann A; Matthaei S; Rosak C; Silvestre L;
Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
[TBL] [Abstract][Full Text] [Related]
47. [For each diabetic the right program. Insulin therapy according to the physiology model].
Bischoff A
MMW Fortschr Med; 2003 Aug; 145(31-32):10. PubMed ID: 14524061
[No Abstract] [Full Text] [Related]
48. Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study.
Shomali ME; Herr DL; Hill PC; Pehlivanova M; Sharretts JM; Magee MF
Diabetes Technol Ther; 2011 Feb; 13(2):121-6. PubMed ID: 21284478
[TBL] [Abstract][Full Text] [Related]
49. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
Pan CY; Sinnassamy P; Chung KD; Kim KW;
Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
[TBL] [Abstract][Full Text] [Related]
50. Effects of mixing glargine and short-acting insulin analogs on glucose control.
Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
[No Abstract] [Full Text] [Related]
51. [When tablets are no longer enough. Which insulin for type 2 diabetic patients?].
MMW Fortschr Med; 2002 Sep; 144(38):58. PubMed ID: 12395711
[No Abstract] [Full Text] [Related]
52. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system.
Wang XL; Lu JM; Pan CY; Mu YM; Dou JT; Ba JM; Wang X
Diabetes Res Clin Pract; 2007 Apr; 76(1):30-6. PubMed ID: 16979255
[TBL] [Abstract][Full Text] [Related]
53. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
Ashwell SG; Amiel SA; Bilous RW; Dashora U; Heller SR; Hepburn DA; Shutler SD; Stephens JW; Home PD
Diabet Med; 2006 Mar; 23(3):285-92. PubMed ID: 16492212
[TBL] [Abstract][Full Text] [Related]
54. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
55. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
Bode BW; Steed RD; Schleusener DS; Strange P
Endocr Pract; 2005; 11(3):157-64. PubMed ID: 16239201
[TBL] [Abstract][Full Text] [Related]
56. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
[No Abstract] [Full Text] [Related]
57. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
[TBL] [Abstract][Full Text] [Related]
58. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
59. [Researchers illuminate diabetes therapy].
Pflege Z; 2014 Feb; 67(2):126. PubMed ID: 24730335
[No Abstract] [Full Text] [Related]
60. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
